PTC Therapeutics, Inc., a South Plainfield, New Jersey-based biopharmaceutical company, has appointed Eric Pauwels as senior vice president and general manager, commercial operations, Americas. He will be responsible for the commercial strategy, organizational build-out and launch of the company's lead product, Translarna (ataluren) in the US, Canada, and Latin America. orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren
PTC Therapeutics is focused on the discovery, development, and commercialization of orally administered, proprietary small-molecule drugs targeting an area of RNA biology, post-transcriptional control. Post-transcriptional control processes are the regulatory events that occur in cells during and after a messenger RNA is copied from DNA through the transcription process. PTC has received conditional marketing authorization in the European Economic Area for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients aged five years and older.
Mr. Pauwels has 33 years of global healthcare experience from several top-tier US and global pharmaceutical companies. Most recently, he was the chief commercial officer at NPS Pharmaceuticals and president of NPS Pharmaceuticals International. From 2005 to 2010, He was senior vice president, global commercial operations, at Shire Human Genetic Therapies, with oversight of more than 400 employees in 30 countries and $800 million in revenues. He also held global marketing and general management functions in the US, Europe and China with Shire, Bayer, Fournier and J&J.
Source: PTC Therapeutics